… Dr. Sumanta (Monty) Kumar Pal, M.D., FASCO highlights some of the top data and presentations being presented in kidney and…
Browsing: Bladder
Introduction The US Food and Drug Administration (FDA) recently approved nogapendekin alfa inbakicept-pmln (Anktiva), used in conjunction with bacillus Calmette-Guérin…
By: Thomas Powles, MD Date: October 25, 2023 An exclusive interview occurred with Dr. Thomas Powles, MD, the lead investigator…
an AML-ALL US Focus Meeting 2023 video
Mark Schoenberg, MD- UrologyGenitourinary (GU) CancerBladder Cancer-The Montefiore Medical Center and The Albert Einstein College of Medicine at UroGen Pharma…
Nataliya Mar, MD Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, provides GU ASCO…
Akasha Dukkipati, MD at City of Hope August 21, 2023 Akasha Dukkipati, MD at City of Hope, conducted an analysis…
In the ever-evolving world of oncology, there is always a beacon of hope on the horizon. The latest such promise…
Infigratinib, an FGFR1-3 inhibitor, has shown promise as an adjuvant therapy for invasive urothelial carcinoma. The FDA has approved infigratinib…
Manojkumar Bupathi, MD, from the Rocky Mountain Cancer Centers, conducted a study to evaluate the effectiveness of sacituzumab govitecan (SG)…
Manojkumar Bupathi, MD, MS, from Rocky Mountain Cancer Centers, conducted a safety analysis on cohort 1 of the TROPHY-U-01 phase…
Advanced Urothelial carcinoma, primarily affecting the urinary system, is a typically aggressive cancer with limited treatment options. Pembrolizumab, an immunotherapy…
Patrizia Giannatempo, MD, from the Fondazione IRCCS Istituto Nazionale dei Tumori, has conducted extensive research on the impact of histology…
Petros Grivas, MD, PhD, an expert in urothelial carcinoma (UC) research at the University of Washington, has made significant contributions…
Bladder Cancer Test: Does GALEAS Bladder aid in the early detection of bladder cancers? Prof. Bryan Dr. Ward Professor…
Bladder cancer test called “GALEAS Bladder” is a DNA-based diagnostic urine test designed to aid in the early detection of…
iFrame is not supported! Pembrolizumab combined with CG0070. How can this help patients with NMIBC? Roger Li Roger Li, MD…
The Roger Li, MD discussed the updated results from the CORE1 trial, which explored the combination of Cretostimogene Grenadorepvec (CG0070),…
Urothelial Cancer: What’s New in 2023? Targeted and Novel Therapies Nataliya Mar MD By Nataliya Mar, MD Good afternoon, everyone.…
rAd-IFNα/Syn3 Phase 3 Trial NMIBC [2022] rAd-IFNα/Syn3 Bladder Cancer Trial It’s an honor to be asked to speak about…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
We are excited to bring new and updated information to share through our Bladder Cancer Video Library. For this video…
Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase…
Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase…
Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video,…
Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video,…
Gary Winzelberg, MD, MPH, Associate Professor, Division of Geriatric Medicine, Associate Director, UNC Palliative Care Program, Director, Hospice, and Palliative…
Gary Winzelberg, MD, MPH, Associate Professor, Division of Geriatric Medicine, Associate Director, UNC Palliative Care Program, Director, Hospice, and Palliative…
William C. Huang, M.D., FACS, Associate Professor and Vice-Chair of Urology at NYU Langone Health, Principal Investigator of the OPTIMA…
Peter H. O’Donnell, MD from the University of Chicago speaks about the ASCO 2021 Abstract – Oral Abstract Session: First-Line…
Jennifer Linehan, M.D., Associate Professor of Urology and Urologic Oncology at Saint John’s Cancer Institute, Investigator of the OLYMPUS trial…
Jennifer Linehan, M.D., Associate Professor of Urology and Urologic Oncology at Saint John’s Cancer Institute, Investigator of the OLYMPUS trial…
Peter H. O’Donnell, MD from the University of Chicago speaks about the ASCO 2021 Abstract – Oral Abstract Session: First-Line…
Petros Grivas, MD, Ph.D. Department Of Medicine, Division Of Medical Oncology, University of Washington; Fred Hutchinson Cancer Research Center, and…
Professor Thomas Powles, MD from Barts Cancer Centre, London, UK speaks about European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance…
Professor Thomas Powles, MD of Barts Cancer Centre, Queen Mary University of London speaks about Seattle Genetics and Astellas Announce…
Arjun Balar, MD from NYU Langone’s Perlmutter Cancer Center discusses Astellas and Seagen Announce Positive Topline Results from Second Cohort…
Yung Lyou, MD from the City of Hope speaks about High-throughput global transcriptional profiling to identify the STAT3 signaling pathway…
Kenny Chin, BS of the Icahn School of Medicine at Mount Sinai speaks about the ASTRO 2020 abstract 4021 Clinical…
Petros Grivas, MD, Ph.D. of the University of Washington; Fred Hutchinson Cancer Research Center speaks about the ESMO 2020 abstract…
We are excited to bring you more new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD.For this…
We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this…
We are excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD.For this video,…
Shilpa Gupta, MD – Cleveland Clinic discusses Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract…
Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder…
Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses if switch maintenance immunotherapy is a standard base treatment…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC answers what is the role of a switch maintenance immune…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses switch maintenance immunotherapy, significantly slows the worsening of a…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial – – Astellas Pharma Inc. (TSE: 4503,…
GRACE is excited to bring you new information in our Bladder Cancer Program. For this first video of 2019, Dr.…
GRACE is excited to bring you new information in our Bladder Cancer Program. For this video, Dr. Ramy Sedhom introduces…
·         At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS)…
Andrew Krivoshik, MD of @AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO. #ESMO2019
Andrew Krivoshik, MD of @AstellasUS discusses the EV_103 phase I trial in locally advanced and first- and second-line metastatic urothelial…
– Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 – Â BOTHELL, Wash.…
he Tisch Cancer Institute Deepens Bladder Cancer Care With New Center of Excellence  (New York – September 12, 2019) The…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab…
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses the broader implications of the SAUL study. Background: Atezo, a…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Challenges Using…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Role Of…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Molecular Characterization &…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Latest In…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Outcomes Of KEYNOTE…
Speaking from the 2018 Genitourinary Cancers Symposium in San Francisco, CA, Peter Black, MD, of the University of British Columbia,…
BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some…
Treatment for muscle-invasive bladder cancer has evolved as medical knowledge has expanded. Jeanny Aragon-Ching, MD, FACP, from Inova Schar Cancer…
In this video, Peter Black, MD, of the University of British Columbia, Vancouver, Canada, speaks to us about the use…
Jeanny Aragon-Ching, MD, FACP, of Inova Schar Cancer Institute, Falls Church, VA, discusses the differences in survival rates of non-urothelial…
The European Medicines Agency have announced their recommendation to restrict the use of pembrolizumab and atezolizumab to the first-line treatment…
The ABACUS trial (NCT02662309), an investigator-initiated Phase II study investigating the safety and efficacy of two cycles of neoadjuvant atezolizumab…
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here,…
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how…
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the first results of the primary analysis of…
Nataliya Mar, MD, UC Irvine Health, shares her Urothelial Carcinoma Abstracts | Enfortumab, Erdafitinib were Effective Based on Data at…
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting…
A variety of highlighly anticipated urological oncology research with great potential was shown at the American Society of Oncology (ASCO)…
Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting urothelial carcinoma therapy updates from the American Society…
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced…
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these…
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy…
Jeanny B. Aragon-Ching, MD, FACP, explains reliable molecular markers that can help identify high-risk muscle-invasive bladder cancer patients who should…
Gary D. Steinberg, MD, explains whether FGFR inhibitors in metastatic bladder cancer have the potential to be practice changing.
Jeanny B. Aragon-Ching, MD, FACP, discusses how new guidelines have changed the treatment of advanced metastatic bladder cancer.
Aman Chauhan, MBBS, University of Kentucky shares Telotristat for Carcinoid Syndrome Diarrhea | Wish for More Trials, Products, Pipeline Drugs…
Aman Chauhan, MBBS, University of Kentucky shares Data Showed Diarrhea From Chemotherapy at Annual Meeting 2018
Aman Chauhan, MBBS, University of Kentucky explains enterade® is a Medical Food | Does Not Need Formal Prescription. OTC at…
Aman Chauhan, MBBS, University of Kentucky explains enterade® Amino Acid Based Rehydration Solution | 70% of Patients Had Benefit in…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Target Tumors More Effectively | Better Combinations, Find…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Annual Meeting Helps Impact Ability to Communicate |…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Moving Toward Precision Medicine | Field is Growing…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Bladder Cancer is No Longer Just One Disease…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Erdafitinib Currently Not FDA-Approved | Granted Breakthrough Designation…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Studies for Fibroblast Growth Factors Receptors | Mutations…
Arlene O. Seifker-Radtke, MD, University of Texas MD Anderson Cancer Center shares Therapy for Metastatic Urothelial Carcinoma | Erdafitnib, a…
Petros Grivas, MD, PhD, University of Washington talks about Dynamic Era of Changes for Urothelial Cancer | Data with FGFR…
Petros Grivas, MD, PhD, University of Washington talks about Whether Genomic Alterations Have Significance | And-Or Predict Response to Individual…
Petros Grivas, MD, PhD, University of Washington talks about Circulating Tumor DNA as a Putative Biomarker | For Patients with…